{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:07:07Z","timestamp":1772856427899,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.vaccine.2012.01.058","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T23:15:13Z","timestamp":1328138113000},"page":"2309-2314","source":"Crossref","is-referenced-by-count":18,"title":["Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers"],"prefix":"10.1016","volume":"30","author":[{"given":"Brandon","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magaly","family":"Blas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Carcamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti","family":"Gravitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.01.058_bib0005","unstructured":"IARC. Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses. Lyon: International Agency for Research on Cancer: vol. 90; 2007 15\u201322 February."},{"key":"10.1016\/j.vaccine.2012.01.058_bib0010","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0015","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0020","series-title":"Third annual poster presentation at Puget Sound partners for global health lecture","article-title":"Feasibility of a community-based voluntary HIV counseling and testing program in commercial sex venues in Lima, Peru","author":"Calhoun","year":"2005"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/sti.2002.003749","article-title":"Cervical smears and human papillomavirus typing in sex workers","volume":"80","author":"Mak","year":"2007","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0030","first-page":"789","article-title":"Detection and typing of human papillomavirus DNAs by restriction endonuclease mapping of the PCR products","volume":"33","author":"Donmez","year":"1997","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/gyno.2001.6244","article-title":"High prevalence of oncogenic human papillomavirus in the genital tract of women with human immunodeficiency virus","volume":"82","author":"Volkow","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.virusres.2006.04.009","article-title":"The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers","volume":"121","author":"Marais","year":"2006","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00007435-200103000-00001","article-title":"Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City","volume":"28","author":"Ju\u00e1rez-Figueroa","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0050","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1128\/JCM.39.12.4344-4348.2001","article-title":"Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes","volume":"39","author":"Touze","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0060","series-title":"IARC","article-title":"Globocan 2002: cancer incidence, mortality, and prevalence worldwide","author":"Ferlay","year":"2004"},{"issue":"49","key":"10.1016\/j.vaccine.2012.01.058_bib0065","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1016\/j.vaccine.2010.09.063","article-title":"Peruvian FSWs: understanding HPV and barriers to vaccination","volume":"28","author":"Brown","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0070","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1128\/CDLI.10.1.108-115.2003","article-title":"Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay","volume":"10","author":"Opalka","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0080","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/CDLI.12.8.959-969.2005","article-title":"Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18","volume":"12","author":"Dias","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15\u201355 years","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.01.058_bib0090","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0095","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1542\/peds.103.6.1243","article-title":"Hepatitis B vaccine administered to children and adolescents at yearly intervals","volume":"103","author":"Halsey","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0100","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2006.09.073","article-title":"Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium","volume":"25","author":"Wouters","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2012.01.058_bib0105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1089\/jwh.2009.1753","article-title":"Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women","volume":"19","author":"Zimmerman","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"issue":"14","key":"10.1016\/j.vaccine.2012.01.058_bib0110","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial","volume":"305","author":"Neuzil","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.01.058_bib0115","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1001\/jama.285.23.2995","article-title":"Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females","volume":"285","author":"Moscicki","year":"2001","journal-title":"JAMA"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2012.01.058_bib0120","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1136\/sti.2006.020081","article-title":"Estimates of the number of female sex workers in different regions of the world","volume":"82","author":"Vandepitte","year":"2006","journal-title":"Sex Transm Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12000965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12000965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T16:23:11Z","timestamp":1593620591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0264410X12000965"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}